These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 24523429)

  • 1. Triptan use after starting prophylactic migraine treatment: a retrospective cohort study in a primary care population.
    Smelt AF; Assendelft WJ; van Dijk CE; Blom JW
    Cephalalgia; 2014 Oct; 34(11):927-32. PubMed ID: 24523429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence with migraine prophylactic treatment and acute migraine medication utilization in the managed care setting.
    Yaldo AZ; Wertz DA; Rupnow MF; Quimbo RM
    Clin Ther; 2008 Dec; 30(12):2452-60. PubMed ID: 19167603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of a 2-year retrospective cohort study of newly prescribed triptan users in European nationwide practice databases.
    Ng-Mak DS; Chen YT; Ho TW; Stanford B; Roset M
    Cephalalgia; 2012 Sep; 32(12):875-87. PubMed ID: 22833612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rates and predictors of starting a triptan: results from the American Migraine Prevalence and Prevention Study.
    Bigal ME; Buse DC; Chen YT; Golden W; Serrano D; Chu MK; Lipton RB
    Headache; 2010 Oct; 50(9):1440-8. PubMed ID: 20533956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of adherence to triptans: factors of sustained vs lapsed users.
    Cady RK; Maizels M; Reeves DL; Levinson DM; Evans JK
    Headache; 2009 Mar; 49(3):386-94. PubMed ID: 19220501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and determinants of migraine prophylactic medication in the Netherlands.
    Rahimtoola H; Buurma H; Tijssen CC; Leufkens HG; Egberts AC
    Eur J Clin Pharmacol; 2002 May; 58(2):149-55. PubMed ID: 12012149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nebivolol and metoprolol for treating migraine: an advance on beta-blocker treatment?
    Schellenberg R; Lichtenthal A; Wöhling H; Graf C; Brixius K
    Headache; 2008 Jan; 48(1):118-25. PubMed ID: 18184294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response.
    Marcus SC; Shewale AR; Silberstein SD; Lipton RB; Young WB; Viswanathan HN; Doshi JA
    Cephalalgia; 2020 Jun; 40(7):639-649. PubMed ID: 32223301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metoprolol and propranolol in the prophylactic treatment of classical and common migraine. A double-blind study.
    Kangasniemi P; Hedman C
    Cephalalgia; 1984 Jun; 4(2):91-6. PubMed ID: 6428749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Migraine treatment with rizatriptan and non-triptan usual care medications: a pharmacy-based study.
    Cady R; Martin V; Adelman J; Diamond M; Sajjan S; Hu XH
    Headache; 2004 Oct; 44(9):900-7. PubMed ID: 15447699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triptans use and overuse: A pharmacoepidemiology study from the French health insurance system database covering 4.1 million people.
    Braunstein D; Donnet A; Pradel V; Sciortino V; Allaria-Lapierre V; Lantéri-Minet M; Micallef J
    Cephalalgia; 2015 Nov; 35(13):1172-80. PubMed ID: 25667299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cross-sectional survey to assess the migraineur's medication decision-making beliefs: determining when a migraine is triptan-worthy.
    Landy SH; Turner IM; Runken MC; Lee M; Sulcs E; Bell CF
    Headache; 2013; 53(7):1134-46. PubMed ID: 23773016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metoprolol and propranolol in migraine prophylaxis: a double-blind multicentre study.
    Olsson JE; Behring HC; Forssman B; Hedman C; Hedman G; Johansson F; Kinnman J; Pålhagen SE; Samuelsson M; Strandman E
    Acta Neurol Scand; 1984 Sep; 70(3):160-8. PubMed ID: 6391066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy of triptans for the abortive treatment of migraine: a multiple treatment comparison meta-analysis.
    Thorlund K; Mills EJ; Wu P; Ramos E; Chatterjee A; Druyts E; Goadsby PJ
    Cephalalgia; 2014 Apr; 34(4):258-67. PubMed ID: 24108308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Responders and non-responders to metoprolol, propranolol and nifedipine treatment in migraine prophylaxis: a dose-range study based on time-series analysis.
    Gerber WD; Diener HC; Scholz E; Niederberger U
    Cephalalgia; 1991 Feb; 11(1):37-45. PubMed ID: 2036669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Patterns of prescription and usage of triptans in Alsace (France): misuse is frequent and avoidable].
    Perearnau P; Vuillemet F; Schick J; Weill G
    Rev Neurol (Paris); 2006 Mar; 162(3):347-57. PubMed ID: 16585890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perinatal use of triptans and other drugs for migraine-A nationwide drug utilization study.
    Tauqeer F; Wood M; Hjorth S; Lupattelli A; Nordeng H
    PLoS One; 2021; 16(8):e0256214. PubMed ID: 34424941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute treatment patterns in patients with migraine newly initiating a triptan.
    Lipton RB; Marcus SC; Shewale AR; Dodick DW; Viswanathan HN; Doshi JA
    Cephalalgia; 2020 Apr; 40(5):437-447. PubMed ID: 32138526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prophylactic measures and acute treatment of migraine].
    Göbel H; Heinze A; Heinze-Kuhn K
    Schmerz; 2006 Nov; 20(6):541-54; quiz 555-6. PubMed ID: 17048020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Geographic variation in the use of triptans and opioids for the acute treatment of migraine attacks.
    Lee JH; Shewale AR; Barthold D; Devine B
    Headache; 2021 Nov; 61(10):1499-1510. PubMed ID: 34841520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.